^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
TROP2-CAR-NK
i
Other names: TROP2-CAR-NK, TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
UT MD Anderson Cancer Center
Drug class:
NK cell stimulant, TROP-2 inhibitor
Related drugs:
1m
Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD) (clinicaltrials.gov)
P1, N=42, Not yet recruiting, M.D. Anderson Cancer Center
New P1 trial • Combination therapy • Minimal residual disease
|
Erbitux (cetuximab) • cyclophosphamide • fludarabine IV • TROP2-CAR-NK • rimiducid (AP1903)
6ms
Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA) (clinicaltrials.gov)
P1, N=54, Recruiting, M.D. Anderson Cancer Center | Trial primary completion date: Apr 2028 --> Apr 2038
Trial primary completion date • Metastases
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
|
PD-L1 expression • BRAF V600E • HR positive • HER-2 negative • BRAF V600 • TROP2 expression
|
cyclophosphamide • fludarabine IV • TROP2-CAR-NK • rimiducid (AP1903)
6ms
Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer (clinicaltrials.gov)
P1/2, N=51, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting
Enrollment open
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
|
BRCA2 mutation • BRCA1 mutation • TROP2 expression
|
cyclophosphamide • fludarabine IV • TROP2-CAR-NK
7ms
Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA) (clinicaltrials.gov)
P1, N=54, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting | Initiation date: Mar 2024 --> Oct 2023
Enrollment open • Trial initiation date • Metastases
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
|
PD-L1 expression • BRAF V600E • HR positive • HER-2 negative • BRAF V600 • TROP2 expression
|
cyclophosphamide • fludarabine IV • TROP2-CAR-NK • rimiducid (AP1903)
8ms
Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA) (clinicaltrials.gov)
P1, N=54, Not yet recruiting, M.D. Anderson Cancer Center
New P1 trial • Metastases
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
|
PD-L1 expression • BRAF V600E • HR positive • HER-2 negative • BRAF V600 • TROP2 expression
|
cyclophosphamide • fludarabine IV • TROP2-CAR-NK • rimiducid (AP1903)
11ms
Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer (clinicaltrials.gov)
P1/2, N=51, Not yet recruiting, M.D. Anderson Cancer Center
New P1/2 trial
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
|
BRCA2 mutation • BRCA1 mutation • TROP2 expression
|
cyclophosphamide • fludarabine IV • TROP2-CAR-NK
Share via
